The U.K. drugmaker GSK reports earnings Wednesday, in the midst of what’s been a perilous season for pharmaceutical results.
GSK’s American depositary receipt has outperformed many of its pharma peers so far this year. Putting aside Eli Lilly and Novo Nordisk —whose new anti-obesity medicines have driven dramatic spikes in their share prices—GSK is among the best performers of the group. The GSK American depositary receipt is up roughly 1% so far this year, while the S&P 500 Pharmaceuticals industry index has fallen 7%.
GSK will for the first time report sales of Arexvy, its new respiratory syncytial virus vaccine that launched this fall. The company expects the drug to grow into a megablockbuster. It competes with a similar shot from Pfizer, which also launched this year.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
These stocks have earnings momentum heading into their reports this weekCNBC Pro screened for the S&P 500 companies reporting this week that analysts are most excited about—leading them to lift their earnings estimates.
더 많은 것을 읽으십시오 »
JetBlue Reports Earnings Soon. What to Expect.The antitrust trial following the Justice Department’s lawsuit to block JetBlue’s proposed merger with Spirit Airlines is finally due to begin after a...
더 많은 것을 읽으십시오 »
AMD Reports Earnings Today. What to Expect.The consensus is that Advanced Micro Devices will report quarterly revenue of $5.7 billion with adjusted earnings per share of 68 cents.
더 많은 것을 읽으십시오 »
SiriusXM Reports Third-Quarter Earnings, Subscribers, AdvertisingThe audio entertainment giant, the home of Howard Stern, is 'very excited' to unveil SiriusXM's next-generation platform in early November, said CEO Jennifer Witz.
더 많은 것을 읽으십시오 »
Fed decision, Mondelez reports, Airbnb earnings: 3 things to watchFed decision, Mondelez reports, Airbnb earnings: 3 things to watch
더 많은 것을 읽으십시오 »
Anheuser-Busch reports higher-than-expected earnings in Q3Anheuser-Busch saw better performance in Q3 of 2023 despite still struggling in the U.S. after controversy surrounding Bud Light’s brief partne...
더 많은 것을 읽으십시오 »